These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20973966)

  • 1. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.
    Miyazaki T; Shimada K; Miyauchi K; Kume A; Tanimoto K; Kiyanagi T; Sumiyoshi K; Hiki M; Mokuno H; Okazaki S; Sato H; Kurata T; Daida H
    Lipids Health Dis; 2010 Oct; 9():122. PubMed ID: 20973966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
    Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V; Malik J; Wichterle D; Simek J; Pisarikova A; Skrha J; Poledne R; Stavek P; Ceska R
    Am Heart J; 2002 Oct; 144(4):E6. PubMed ID: 12360175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
    Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
    J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
    Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
    Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy.
    Hahmann HW; Bunte T; Hellwig N; Hau U; Becker D; Dyckmans J; Keller HE; Schieffer HJ
    Am J Cardiol; 1991 May; 67(11):957-61. PubMed ID: 2018014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.